




Fig. 1




Fig. 2

Increase in truncation in CompAb1 and none in variants mAb1 or mAb2 after incubation in IgG-depleted human serum




Fig. 3

4/21




Fig. 4

5/21




Fig. 5C

Fig. 5B

Fig. 5A

6/21

Binding to Activated (CD25⁺) Human Primary T Cells




Fig. 6

7/21

Binding to CD69⁺ Cynomolgus Monkey Primary T Cells




Fig. 7

Fc-Mediated NFAT Activity in Jurkat/NFAT-Luc/hFcγR3a and Jurkat/NFAT-Luc/MfFcγR3a Effector Cells




Fig. 8B





Fig. 8D


9/21

Antibody Mediation of ADCC Against Jurkat T Cells Engineered to Express Human or Cynomolgus Monkey G1TR

Donor 6700R Human Primary NK Cells in the Presence of



Donor 6500V Human Primary NK Cells in the Presence of



10/21

Antibody Mediation of ADCC Against Human Primary T Cells

Donor 04003 Human Primary NK Cells in the Presence of




Fig. 10A




Fig. 10B

11/21

Donor 05100 Human Primary NK Cells in the Presence of




Fig. 10C




Fig. 10D

Antibody Mediation of ADCC of Jurkat T Cells Engineered to Express Human or Cynomolgus Monkey GITR

12/21






Fig. 11A

Fig. 11B

Fig. 11C

Antibody Effect on Anti-CD3-Mediated Primary CD4⁺ T-Cell Proliferation



Effect of Anti-GlTR Antibody on Human GlTR Binding to Human GlTR-L




Fig. 13




Fig. 14

mAb1 Does Not Form Immune Complexes Capable of Binding C1q When Incubated with Soluble G1TR




Fig. 15A

Fig. 15B

mAb1 in Combination with Cemiplimab Enhances IL-2 Release from Anti-CD3-Stimulated Primary CD3⁺ T Cells in the Presence of Human PD-L1




Fig. 16A




Fig. 16B

Anti-GITR Antibodies CompAb1 and Associated Variants Deplete Intratumoral T regulatory cells and Increase the CD8+ T-cell/ T-regulatory Cell Ratio




Fig. 17

Administration of 1 mg/kg Cemiplimab in Combination with 10 mg/kg mAb1 Results in Greater Reduction in MC38 Tumor Growth Compared with Cemiplimab Alone

Cohort	Tumor size (mm ³) at Day 20	Significance at Day 20
1 mg/kg IgG4P Isotype control + 10 mg/kg IgG1 Isotype control	659.84 = 660	
1 mg/kg Cemiplimab + 10 mg/kg IgG1 Isotype Control	289.34 = 290	*** p<0.001
1 mg/kg Cemiplimab + 10 mg/kg mAb1	66.98 = 67	**** p<0.0001
1 mg/kg Cemiplimab + 1 mg/kg mAb1	227.355 = 227	**** p<0.0001
1 mg/kg Cemiplimab + 0.1 mg/kg mAb1	285.375 = 285	**** p<0.0001

Statistical significance was determined using a two-way RM ANOVA followed with Tukey's post-hoc multiple comparisons test ($\alpha=0.05$). The “*” symbol indicates statistical significance in comparison with the 1 mg/kg IgG4P isotype control + 10 mg/kg IgG1 isotype control treatment group. Increasing numbers of symbols represent increasing significance: 1x=adjusted p<0.05; 2x= adjusted p<0.01; 3x=adjusted p<0.001; 4x=adjusted p<0.0001. Administrations of doses are indicated with red arrowheads along the x-axis.




Fig. 18

Administration of 1 mg/kg Cemiplimab in Combination with 10 mg/kg mAb1 Results in Higher Frequency of Tumor Clearance Compared with 1 mg/kg Cemiplimab Alone




Fig. 19A




Fig. 19B

Fig. 19C




Fig. 19D

Fig. 19E

21/21

Administration of 1 mg/kg Cemiplimab in Combination with 10 mg/kg mAb1 Results in Significantly Greater Survival Compared with Cemiplimab Alone




Fig. 20